The potential of LAG-3 targeting therapy to treat a number of ailments, particularly cancer, autoimmune diseases, and inflammatory diseases, has attracted a lot of attention to the global market.

LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year's ASCO conference after trial results showed their potential as next-generation ...

LAG-3 is a popular target, and following after is a clutch of drugs in mid-stage development, including Immutep's soluble LAG-3 protein eftilagimod alpha, Novartis/Immutep's leramilimab, Incyte's ...

What happened: The world's largest meme coin rose over 3% in the last 24 hours, while its trading volume spiked 30% to over $2 billion. Widely followed cryptocurrency analyst Ali Martinez ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...